Study In Patients With Kidney Cancer Treated With Sutent
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
Advanced or Metastatic Renal Cell Carcinoma|Renal Cancer
DRUG: Sutent
Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib, 36 months
Dose modifications, 36 months|Incidence of new diagnosed hypertension, 36 months|Incidence of new diagnosed hypothyroidism, 36 months|Safety of sunitinib malate in "real-life" setting, 36 months|Efficacy of sunitinib malate in "real-life" setting, 36 months
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy